PPT-CV safety & Outcome trials of
Oral Antidiabetics Adverse CV events led the FDA to require demonstration of CV safety for new glucoselowering drugs UGDP study tolbutamide discontinued due to increased
Download Presentation
"CV safety & Outcome trials of" is the property of its rightful owner. Permission is granted to download and print materials on this website for personal, non-commercial use only, provided you retain all copyright notices. By downloading content from our website, you accept the terms of this agreement.
Presentation Transcript
Transcript not available.